Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0602 • ACR Convergence 2022
Cellworks Biosimulation Model (CBM) for Rheumatoid Arthritis (RA), Accurately Captures Patient’s Disease Activity at the Molecular Level Using Their Omics Data and Can Bring Personalization to Treatment Selection in RA
Himanshu Grover¹, Ansu Kumar¹, Anushua Chakraborty¹, Susheel George Chandy¹, Vivek Patil¹, Swati Khandelwal¹, Vishwas Joseph¹, Deepak Anil Lala¹, Prashant Ramachandran Nair¹, Karthik Sundara Raju¹, Kunal Ghosh Roy¹, Shahabuddin Usmani¹, Aftab Alam¹, Swaminathan Rajagopalan¹, Yatin Mundkur¹ and Andrew Concoff², ¹Cellworks Group Inc., South San Francisco, CA, ²United Rheumatology, Hauppauge, NY
Background/Purpose: Patients with RA demonstrate varied individual responses to the many treatment options available. In the absence of accurate, precision prediction of medication response, current…
Abstract Number: 0620 • ACR Convergence 2022
Neovascularization Is Altered by Rheumatoid Arthritis Synovial Fibroblasts and Canstatin in Vitro and in Vivo
Corinna Heck¹, Daria Kürsammer¹, Klaus Frommer², Mona Arnold³, Stefan Rehart⁴, Ulf Müller-Ladner⁵ and Elena Neumann³, ¹Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Bad Nauheim, Germany, ²Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, ³JLU Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ⁴Agaplesion Markus Hospital, Dpt of Orthopaedics and Trauma Surgery, Frankfurt, Germany, ⁵JLU Campus KK, Bad Nauheim, Germany
Background/Purpose: In the pathogenesis of rheumatoid arthritis (RA), neovascularization is increased in the activated and inflamed synovium. RA synovial fibroblasts (RASF) are key players in…
Abstract Number: 0723 • ACR Convergence 2022
Risk of Major Adverse Cardiovascular and Venous Thromboembolism Events in Patients with Rheumatoid Arthritis Exposed to JAK Inhibitors versus Adalimumab: A Nationwide Cohort Study
Lea Hoisnard¹, Laura Pina Vegas², Rosemary Dray-Spira³, Alain Weill³, Mahmoud Zureik³ and Emilie sbidian⁴, ¹Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France, ²Service de Rhumatologie, AP-HP, Hôpital Henri Mondor, Créteil, France, ³EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France, ⁴Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France
Background/Purpose: To assess the risk of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) among patients initiating a Janus kinase inhibitor (JAKi) (tofacitinib…
Abstract Number: 0787 • ACR Convergence 2022
Relationship Between Humoral and Cellular Immune Responses in Persons with Rheumatoid Arthritis Following a Third Dose of COVID-19 Vaccine
Sara Tedeschi¹, Daniel Solomon¹, Yuezhou Chen², Jack Ellrodt¹, Mary Grace Whelan¹, Jacklyn Stratton¹, Keigo Hayashi³, Noah Whiteman², Lin Chen¹, Ifeoluwakiisi Adejoorin¹, Kathryne Marks¹, Emma Gomez-Rivas¹, Deepak Rao¹, Anna Jonsson¹ and Duane Wesemann², ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Okayama, Japan
Background/Purpose: DMARDs that treat RA may reduce immune responses to COVID-19 vaccination. We compared measures of humoral and cell-mediated immunity in RA patients before and…
Abstract Number: 0892 • ACR Convergence 2022
Predicting Value of Circulating Semaphorin 4A for Rheumatoid Arthritis Progression and Response to Treatment
Jérôme Avouac¹, Eloïse Vandebeuque², Alice Combier³, lucile poiroux³, Alexia Steelandt³, Margaux Boisson³, Virginie Gonzalez⁴, Anne Cauvet⁴, Thomas Barnetche⁵, Marie Truchetet⁶, Christophe Richez⁷ and Yannick Allanore⁸, ¹University of Paris, Paris, France, ²hôpital Cochin, AP-HP AP-HP.Centre - Université Paris Cité, Paris, France, ³Hôpital Cochin, AP-HP.Centre - Université Paris Cité, Paris, France, ⁴INSERM U1016, Institut Cochin, Paris, France, ⁵CHU Bordeaux, Bordeaux, France, ⁶Bordeaux University Hospital, Bordeaux, France, ⁷Université de Bordeaux, Bordeaux, France, ⁸Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: The lack of validated tools to predict rheumatoid arthritis (RA) disease course warrants the development of new reliable biomarkers. We have previously detected increased…
Abstract Number: 0908 • ACR Convergence 2022
The Association of Cardiovascular Comorbidities with Remission in Rheumatoid Arthritis Patients Undergoing Treatment with Baricitinib and Conventional Synthetic DMARDs: A Post-Hoc Analysis
Arkady Manning-Bennett¹, Ashley Hopkins², Michael Sorich², Susanna Proudman³, David Foster¹, Ahmad Abuhelwa² and Michael Wiese¹, ¹University of South Australia, Adelaide, Australia, ²Flinders University, Adelaide, Australia, ³Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease that is characterised by inflammation in the synovium of diarthrodial joints and low-level inflammation in multiple…
Abstract Number: 0924 • ACR Convergence 2022
Vitamin B12 Status and Hyperhomocysteinemia in Patients with Rheumatoid Arthritis Treated with Methotrexate and Folic Acid
Aakash V Patel¹, Sarah L Morgan¹, Ralph Green², Maria Danila¹, Tony R Merriman¹, Keith Wanzeck¹, Hamdy Ahmed³ and Angelo Gaffo¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Departments of Pathology and Medicine, University of California Davis at Sacramento, Sacramento, CA, ³University of South Alabama, Mobile, AL
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory arthritis in which the immune system targets synovial joints. Methotrexate, a dihydrofolate reductase and aminoimidazole-4-carboxamide ribonucleotide transformylase inhibitor,…
Abstract Number: 0983 • ACR Convergence 2022
Hydroxychloroquine Use and Heart Failure with Preserved Ejection Fraction in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Jake Altier, Fedelis Mutiso, Paul Nietert, Sheldon Litwin and Jim Oates, Medical University of South Carolina, Charleston, SC
Background/Purpose: Initially used as an antimalarial, hydroxychloroquine (HCQ) is standard of care treatment for systemic lupus erythematosus (SLE) and is used as monotherapy or adjunct…
Abstract Number: 1199 • ACR Convergence 2022
Validation of New Medication User Definitions in Single-Specialty EHR Data
Jeffrey Curtis¹, Yujie Su², Michael george³, Cassie Clinton², Patrick Stewart⁴, Tim Buekelman⁵ and Fenglong Xie², ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³UPENN, Philadelphia, PA, ⁴Bendcare, Boca Raton, FL, ⁵FASTER, Hoover, AL
Background/Purpose: New user designs are standard in many pharmacoepidemiology studies, but a first prescription appearance in electronic health record (EHR) data may not always represent…
Abstract Number: 1275 • ACR Convergence 2022
Pneumococcal Vaccination Compliance Rate Among Lupus and Rheumatoid Arthritis Patients in Rheumatology Fellow’s Cllinic
Sana Kang¹, George Gennaoui² and J. Patricia Dhar³, ¹Ascension St John Hospital, Chesterfield, MO, ²Ascension St. John Hospital, St. Clair Shores, MI, ³Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI
Background/Purpose: The US Center for Disease Control and Prevention recommends that adults ages 19 years and older, with immunocompromising conditions should receive a dose of…
Abstract Number: 1392 • ACR Convergence 2022
Comparing Data on Rheumatoid Arthritis (RA) Disease Status Using Patient Reported Outcome Measures (PROMS) RAID/RAPID-3/Self-Reported DAS28 in Remote Electronic Monitoring During the COVID-19 Pandemic with Face-To-Face Clinical Evaluation (DAS28-CRP) Performed Pre-Pandemic
Maria Mirza¹, Kaiyang Song¹, Madiha Ashraf², Anushka Soni³, John Jackman³ and Raashid Luqmani¹, ¹Oxford University Hospital, Oxford, United Kingdom, ²Oxford Universtiy Hospital, Oxford, United Kingdom, ³Oxford University Hospital, Oxford, England, United Kingdom
Background/Purpose: During the COVID-19 pandemic, asynchronous consultations were introduced due to the significant backlog of patients with Rheumatoid arthritis awaiting clinical review. PROMs including Self-Reported…
Abstract Number: 1408 • ACR Convergence 2022
In RA Patients Without Prevalent CVD, Incident CVD Is Only Associated with Traditional Risk Factors: A 20-year Follow up in the CARRÉ Cohort Study
Reinder Raadsen¹, Rabia Agca², Maarten Boers³, Vokko van Halm², Mike Peters⁴, Yvo Smulders², Joline Beulens², Marieke Blom², Coen Stehouwer⁵, Alexandre Voskuyl², Willem Lems⁶ and Michael Nurmohamed⁷, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands, ³Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁴Amsterdam UMC; UMC Utrecht, Amsterdam, Netherlands, ⁵MUmc, Amsterdam, Netherlands, ⁶Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁷Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: We have documented that patients with rheumatoid arthritis (RA) are at increased risk to develop cardiovascular disease (CVD) compared to the general population, even…
Abstract Number: 1426 • ACR Convergence 2022
Year-two Follow-up Results of an Observational Study Conducted in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis Patients Treated with Infliximab Biosimilar CT-P13 in a Real-life Setting
Bruno Fautrel¹, Maryse Assing², Nadir Mammar², Yves Brault² and Hubert Marotte³, ¹Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ²Pfizer, Paris, France, ³INSERM 1059, Saint-Etienne, France
Background/Purpose: ReFLECT study has been carried out to investigate real life use of CT-P13, the first monoclonal antibody biosimilar to infliximab (IFX) originator.Methods: ReFLECT is…
Abstract Number: 1590 • ACR Convergence 2022
Pain and Treatment Switching Among Patients in the CorEvitasTM Rheumatoid Arthritis Registry
Joshua Baker¹, J Morel Symons², Jud C Janak³, Oksana Pugach³, Elizabeth Kohl³, Miao Yu³, Dave Webb⁴, Alan A Martin⁴, Didier Saurigny⁵ and Marguerite Bracher⁵, ¹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ²GlaxoSmithKline, Collegeville, PA, ³CorEvitas, LLC, Waltham, MA, ⁴GlaxoSmithKline, Brentford, United Kingdom, ⁵GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: For many patients with RA on targeted therapies, the chronic burden of pain leads to therapies being deemed suboptimally effective and may affect treatment…
Abstract Number: 1667 • ACR Convergence 2022
Pre-existing Rheumatoid Arthritis Patients Initiating Immune Checkpoint Inhibitors for Cancer Treatment: A Comparative Cohort Study Investigating RA Flare and Mortality
Kaitlin McCarter¹, Taylor Wolfgang¹, Senada Arabelovic¹, Xiaosong Wang¹, Kazuki Yoshida¹, Emily Banasiak¹, Grace Qian¹, Emily Kowalski¹, Kathleen Vanni¹, Nicole LeBoeuf¹, Elizabeth Buchbinder¹, Lydia Gedmintas¹, Lindsey MacFarlane¹, Deepak Rao¹, Nancy Shadick¹, Ellen Gravallese² and Jeffrey Sparks³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: For patients with pre-existing RA, immune checkpoint inhibitors (ICIs) for cancer treatment may trigger RA flares or other immune-related adverse events. Underlying altered immunity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].